COVID-19 in a country with a very high prevalence of diabetes: The impact of admission hyperglycaemia on mortality.
Carlos Martinez MurrilloChristian Omar Ramos-PeñafielLourdes Basurto-AcevedoLourdes Josefina Balcázar-HernándezKaren PellónEder Flores LópezBeatriz Li GómezMercedes Estefania LedesmaRodrigo Rivera TapiaElizabeth Madera MaldonadoMonica Bejarano RosalesGilberto Barranco-LampónJuan Francisco ZazuetaPublished in: Endocrinology, diabetes & metabolism (2021)
Admission hyperglycaemia is presented in 48.5% of COVID-19 patients. Diabetes and admission hyperglycaemia are associated with the severity of disease and mortality. This study shows the devastating conjunction of hyperglycaemia and COVID-19. Clinical trial registration: Clinical characteristics of patients with COVID-19, DI/20/204/04/41 (Hospital General de Mexico) and NR-13-2020 (Hospital Regional de Alta Especialidad Ixtapaluca).
Keyphrases
- sars cov
- coronavirus disease
- emergency department
- clinical trial
- type diabetes
- cardiovascular disease
- cardiovascular events
- healthcare
- risk factors
- acute care
- respiratory syndrome coronavirus
- study protocol
- open label
- biofilm formation
- staphylococcus aureus
- pseudomonas aeruginosa
- phase ii
- insulin resistance
- weight loss
- phase iii
- candida albicans